Tags

Type your tag names separated by a space and hit enter

Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.
Expert Opin Drug Metab Toxicol. 2008 Mar; 4(3):311-24.EO

Abstract

BACKGROUND

Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to rhIGFBP-3, was developed in an attempt to prolong the half-life of IGF-I and potentially reduce side effects. It is administered as a once-daily subcutaneous injection. Treatment with rhIGF-I has been explored in a number of growth and endocrine disorders.

OBJECTIVE

To review the published literature regarding the pharmacokinetics, safety profile and clinical efficacy of Mecasermin rinfabate.

METHODS

A comprehensive search via the NCBI PubMed portal was performed using the search terms rhIGF-I/rhIGFBP-3 complex, iPLEX and Somatokine.

RESULTS

The effects of Mecasermin rinfabate have been explored in a number of clinical situations including diabetes, severe insulin resistance, osteopaenia, burns and growth hormone insensitivity syndrome, with outcomes similar to those of rhIGF-I alone.

CONCLUSIONS

The biological effects of Mecasermin rinfabate are largely similar to those previously reported with rhIGF-I. There are little published data pertaining to pharmacokinetic properties in human subjects, and the side effect profile appears similar to that of rhIGF-I alone.

Authors+Show Affiliations

University of Cambridge, Department of Paediatrics, Addenbrookes Hospital, Box 116, Hills Road, Cambridge CB2 2QQ, UK.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18363546

Citation

Williams, Rachel M., et al. "Mecasermin Rinfabate: rhIGF-I/rhIGFBP-3 Complex: IPLEX." Expert Opinion On Drug Metabolism & Toxicology, vol. 4, no. 3, 2008, pp. 311-24.
Williams RM, McDonald A, O'Savage M, et al. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. Expert Opin Drug Metab Toxicol. 2008;4(3):311-24.
Williams, R. M., McDonald, A., O'Savage, M., & Dunger, D. B. (2008). Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. Expert Opinion On Drug Metabolism & Toxicology, 4(3), 311-24. https://doi.org/10.1517/17425255.4.3.311
Williams RM, et al. Mecasermin Rinfabate: rhIGF-I/rhIGFBP-3 Complex: IPLEX. Expert Opin Drug Metab Toxicol. 2008;4(3):311-24. PubMed PMID: 18363546.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. AU - Williams,Rachel M, AU - McDonald,Anna, AU - O'Savage,Martin, AU - Dunger,David B, PY - 2008/3/28/pubmed PY - 2008/8/13/medline PY - 2008/3/28/entrez SP - 311 EP - 24 JF - Expert opinion on drug metabolism & toxicology JO - Expert Opin Drug Metab Toxicol VL - 4 IS - 3 N2 - BACKGROUND: Mecasermin rinfabate (iPLEX), comprising rhIGF-I complexed to rhIGFBP-3, was developed in an attempt to prolong the half-life of IGF-I and potentially reduce side effects. It is administered as a once-daily subcutaneous injection. Treatment with rhIGF-I has been explored in a number of growth and endocrine disorders. OBJECTIVE: To review the published literature regarding the pharmacokinetics, safety profile and clinical efficacy of Mecasermin rinfabate. METHODS: A comprehensive search via the NCBI PubMed portal was performed using the search terms rhIGF-I/rhIGFBP-3 complex, iPLEX and Somatokine. RESULTS: The effects of Mecasermin rinfabate have been explored in a number of clinical situations including diabetes, severe insulin resistance, osteopaenia, burns and growth hormone insensitivity syndrome, with outcomes similar to those of rhIGF-I alone. CONCLUSIONS: The biological effects of Mecasermin rinfabate are largely similar to those previously reported with rhIGF-I. There are little published data pertaining to pharmacokinetic properties in human subjects, and the side effect profile appears similar to that of rhIGF-I alone. SN - 1742-5255 UR - https://www.unboundmedicine.com/medline/citation/18363546/Mecasermin_rinfabate:_rhIGF_I/rhIGFBP_3_complex:_iPLEX_ L2 - https://www.tandfonline.com/doi/full/10.1517/17425255.4.3.311 DB - PRIME DP - Unbound Medicine ER -